NasdaqCM:SLSBiotechs
SELLAS Life Sciences’ AML Pipeline Adds Key Clinical Checkpoints For Investors
SELLAS Life Sciences Group (NasdaqCM:SLS) has begun a Phase 2 trial of SLS009 in first line acute myeloid leukemia (AML), targeting high risk patient subgroups.
The company plans to present new preclinical data for SLS009, including activity in difficult to treat AML mutations, at an upcoming AACR meeting.
SELLAS is progressing toward the final analysis of the Phase 3 REGAL trial of its GPS cancer vaccine in AML, with trial oversight ongoing and positive trends in patient outcomes...